News
Thermo Fisher shows signs of post-COVID recovery, but modest growth, valuation risks, and macro pressures warrant caution.
The US Food and Drug Administration has approved only a handful of cell and gene therapies, but over 1,000 candidates are now in clinical trials, creating a demand for pharmaceutical services that ...
24/7 Wall St. on MSN7d
4 High-Yield Blue-Chip Pharmaceutical Giants Offer Huge Total Return PotentialHere are four high-yield blue-chip pharmaceutical stocks positioned to outperform and offer huge total return potential.
Americans cannot absorb billions in added drug price hikes as a result of ill-designed and poorly timed tariff increases.
Industry observers, concerned about FIS’s future, questioned whether the Ferrari family, its owner, could continue to run a company that had grown to over 2,000 employees and 300 customers.
News Nation on MSN7d
RFK Jr. defends vaccine panel overhaul, vows safety testing for all shotsKennedy says the new advisory committee will be free of pharmaceutical conflicts and promises autism studies on childhood ...
A 492-strong Cardiff-based pharmaceutical firm has posted a fall in turnover and profits in its latest year amid a decrease ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback